HealthCare Royalty Partners

ADC Therapeutics strikes a $325M royalty deal to fuel its cancer drug strategy
MedCity News
Fri, 08/27/21 - 10:52 am
ADC Therapeutics
HealthCare Royalty Partners
Zynlonta
large cell B-cell lymphoma
Nektar sells off royalties on its 2 approved drugs for $150M in cash, redoubling focus on I-O candidates
Endpoints
Wed, 12/23/20 - 10:44 am
Nektar Therapeutics
Adynovate
Movantik
HealthCare Royalty Partners
La Jolla inks royalty deal to support Giapreza launch
Biopharma Dive
Tue, 05/15/18 - 09:26 am
La Jolla Pharmaceutical
HealthCare Royalty Partners
Giapreza
drug launches
shock